Personalis (NASDAQ:PSNL) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Personalis (NASDAQ:PSNL) issued its earnings results on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04), FiscalAI reports. Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $22.36 million for the quarter, compared to the consensus estimate of $16.69 million.

Personalis Stock Performance

PSNL stock traded up $0.08 during midday trading on Wednesday, reaching $13.60. The company’s stock had a trading volume of 636,523 shares, compared to its average volume of 2,557,166. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -13.34 and a beta of 2.27. Personalis has a 1 year low of $3.84 and a 1 year high of $16.39. The stock has a fifty day simple moving average of $12.21 and a two-hundred day simple moving average of $9.25.

Analyst Ratings Changes

Several analysts have commented on PSNL shares. TD Cowen reiterated a “buy” rating on shares of Personalis in a research note on Wednesday, July 15th. Lake Street Capital lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research note on Monday, July 20th. Morgan Stanley upped their price objective on Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. BTIG Research boosted their price target on shares of Personalis from $11.00 to $16.25 and gave the stock a “buy” rating in a research report on Monday, July 20th. Finally, Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Personalis presently has a consensus rating of “Hold” and a consensus target price of $14.25.

Insider Activity

In other news, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the transaction, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the completion of the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock worth $5,599,929 in the last ninety days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Personalis

Large investors have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. boosted its stake in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Personalis by 1,332.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock worth $11,531,000 after buying an additional 1,347,439 shares in the last quarter. Kennedy Capital Management LLC lifted its holdings in Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after buying an additional 1,281,695 shares during the period. First Manhattan CO. LLC. purchased a new stake in Personalis during the fourth quarter worth $2,976,000. Finally, Ameriprise Financial Inc. boosted its position in Personalis by 1,172.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 329,865 shares of the company’s stock valued at $2,164,000 after acquiring an additional 303,933 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.